Viewing Study NCT01828034


Ignite Creation Date: 2025-12-25 @ 2:22 AM
Ignite Modification Date: 2025-12-26 @ 6:04 AM
Study NCT ID: NCT01828034
Status: COMPLETED
Last Update Posted: 2020-11-17
First Post: 2013-04-05
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Sponsor: Memorial Sloan Kettering Cancer Center
Organization: